^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Fumena (vorolanib)

    i
    Other names: X-82, CM-082, challenge meditech 082
    Company:
    Betta Pharma, Tyrogenex
    Drug class:
    VEGFR inhibitor, PDGFR inhibitor, Tyrosine kinase inhibitor, CSF-1R inhibitor
    Related drugs:
    1m
    A Clinical Study on the Efficacy and Safety of Sintilimab Combined with Vorolanib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (ChiCTR2500110574)
    P2, N=48, Not yet recruiting, Third Medical Center, Chinese PLA General Hospital; Chinese PLA General Hospital
    New P2 trial • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Tyvyt (sintilimab) • Fumena (vorolanib)
    1m
    Efficacy Evaluation of Vorolanib Combined with Sintilimab as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): A ​​Multi-center, Single-Arm Study​ (ChiCTR2500107728)
    P4, N=35, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University​; The First Affiliated Hospital of Zhengzhou University?
    New P4 trial
    |
    Tyvyt (sintilimab) • Fumena (vorolanib)
    3ms
    A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI (clinicaltrials.gov)
    P3, N=116, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P3 trial
    |
    sunitinib • everolimus • Fumena (vorolanib)
    3ms
    Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=11, Terminated, Washington University School of Medicine | Active, not recruiting --> Terminated; Insufficient Funding/Staff
    Trial termination
    |
    Tecentriq (atezolizumab) • Fumena (vorolanib)
    6ms
    A prospective, single-arm phase I/II clinical study of befotertinib in combination with vorolanib neoadjuvant in patients with stage II-IIIB EGFR-positive non-small cell lung cancer (ChiCTR2500103324)
    P1/2, N=39, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Semena (befotertinib) • Fumena (vorolanib)
    6ms
    Efficacy and Safety of Vorolanib Monotherapy or in Combination with Toripalimab as Adjuvant Therapy for Intermediate-High Risk Early-Stage/Mid-Stage Renal Cancer Patients After Surgery: A Multicenter, Randomized, Double-Arm, Phase II Exploratory Study. (ChiCTR2500101854)
    P2, N=60, Recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P2 trial
    |
    PD-1 (Programmed cell death 1)
    |
    Loqtorzi (toripalimab-tpzi) • Fumena (vorolanib)
    6ms
    Efficacy and safety of Vorolanib in patients with inoperable progressive or symptomatic desmoid tumors:A prospective, single-arm, phase II study (ChiCTR2500101139)
    P2, N=18, Recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P2 trial
    |
    Fumena (vorolanib)
    9ms
    VERONA: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=27, Completed, EyePoint Pharmaceuticals, Inc. | Recruiting --> Completed
    Trial completion
    |
    Fumena (vorolanib)
    11ms
    Efficacy and Safety of Vorolanib Combined with Toripalimab as First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter, Open-Label Clinical Study (ChiCTR2400094340)
    P2, N=60, Recruiting, Xi'an Jiaotong University Second Affiliated Hospital; Xi'an Jiaotong University Second Affiliated Hospital
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • Fumena (vorolanib)
    11ms
    The study on efficacy and safety of Ensatinib combined with Vorolanib in the treatment of advanced non-small cell lung cancer with ALK positivity and high PD-L1 expression (ChiCTR2400093433)
    P1/2, N=49, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • PD-L1 overexpression • ALK positive
    |
    Fumena (vorolanib)
    1year
    Vorolanib in the Second-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=39, Recruiting, Jinling Hospital, China
    New trial • Metastases
    |
    Fumena (vorolanib)
    1year
    CA209-982: Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors (clinicaltrials.gov)
    P1/2, N=88, Completed, Vanderbilt-Ingram Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Apr 2024
    Trial completion • Trial completion date • Combination therapy • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Opdivo (nivolumab) • Fumena (vorolanib)